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Abstract
Sickle cell disease (SCD) is one of the most common inherited
diseases in the world and the patients present notorious clinical
heterogeneity. It is known that patients with SCD present activation of
the blood coagulation and fibrinolytic systems, especially during
vaso-occlusive crises, but also during the steady state of the disease.
We determined if the presence of the factor V gene G1691A mutation
(factor V Leiden), the prothrombin gene G20210A variant, and meth-
ylenetetrahydrofolate reductase (MTHFR) C677T polymorphism may
be risk factors for vascular complications in individuals with SCD. We
studied 53 patients with SCD (60% being women), 29 with SS (sickle
cell anemia; 28 years, range: 13-52 years) and 24 with SC (sickle-
hemoglobin C disease; 38.5 years, range: 17-72 years) hemoglobin-
opathy. Factor V Leiden, MTHFR C677T polymorphism, and pro-
thrombin G20210A variant were identified by PCR followed by
further digestion of the PCR product with specific endonucleases. The
following vascular complications were recorded: stroke, retinopathy,
acute thoracic syndrome, and X-ray-documented avascular necrosis.
Only one patient was heterozygous for factor V Leiden (1.8%) and
there was no prothrombin G20210A variant. MTHFR 677TT poly-
morphism was detected in 1 patient (1.8%) and the heterozygous form
677TC was observed in 18 patients (34%, 9 with SS and 9 with SC
disease), a prevalence similar to that reported by others. No associa-
tion was detected between the presence of the MTHFR 677T allele and
other genetic modulation factors, such as α-thalassemia, ß-globin
gene haplotype and fetal hemoglobin. The presence of the MTHFR
677T allele was associated with the occurrence of vascular complica-
tions in SCD, although this association was not significant when each
complication was considered separately. In conclusion, MTHFR C677T
polymorphism might be a risk factor for vascular complications in
SCD.
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Introduction
Sickle cell disease (SCD) is one of the
most common inherited diseases in the world.
In Brazil, 700 to 1000 infants with SCD are
estimated to be born each year (1). Even
with the same inherited DNA mutation within
the ß-globin gene, patients present a notori-
ous clinical heterogeneity. Additional ge-
netic factors such as α-thalassemia, fetal
hemoglobin synthesis, and ß-globin haplo-
type have been identified, but none of these
can fully explain the differences in clinical
expression observed in these patients. Prob-
ably, there are other elements that contribute
to the many phenotypes of the disease (2-5).
It has been known for a long time that
patients with SCD show activation of the
blood coagulation and fibrinolytic systems,
as well as increased platelet activity and
consumption of coagulation inhibitors, es-
pecially during vaso-occlusive crises, but
also during the steady state of the disease (6-
9). Vascular complications are an important
and perplexing aspect of the clinical spec-
trum of sickle cell anemia, although there is
controversial evidence surrounding the role
of thrombosis in this complication (10,11).
Because of the importance of vascular com-
plications in the pathophysiology of SCD, a
number of genetic polymorphisms associ-
ated with thrombophilia have been studied
as potential genetic modifiers of SCD.
In the present study, we investigated the
hypothesis that the presence of the factor V
gene G1691A mutation (factor V Leiden),
the prothrombin gene G20210A variant, and
MTHFR (methylenetetrahydrofolate reduc-
tase) C677T polymorphism may be a risk
factor for vascular complications in indi-
viduals with SS and SCD.
Patients and Methods
We evaluated 53 patients of African de-
scent with SCD, 29 with SS (sickle cell
anemia) and 24 with SC (sickle-hemoglobin
C disease) hemoglobinopathy. The study
population consisted of 32 women and 21
men. The following vascular complications
were identified: stroke by focal neurologic
deficit and computed tomography, retinopa-
thy by ophthalmoscopic fundus examina-
tion, acute thoracic syndrome by clinical
and radiological findings, and avascular ne-
crosis (AVN) of femoral or humeral heads
by X-rays. All patients, including those with
vascular complications, were on oral folate
administration (5 mg/day).
The study was approved by the local
Ethics Committee on human research. After
written informed consent was obtained, ap-
proximately 5 mL whole blood was col-
lected in EDTA and stored at -4ºC until
DNA extraction. Factor V Leiden mutation,
MTHFR C677T polymorphism, and pro-
thrombin G20210A variant were identified
by PCR followed by further digestion of the
PCR product with specific endonucleases,
as described in Refs. 12-14.
The significance of the difference between
medians was determined by the Mann-Whit-
ney U-test. Fisher’s exact test was used to
compare the frequency of observations in con-
tingency tables. Odds ratios (OR), as an esti-
mate of relative risk, and 95% confidence
intervals (95% CI) were calculated using stand-
ard methods. A two-tailed P < 0.05 value was
considered to be statistically significant. Sta-
tistical tests were performed using the Instat2
software (GraphPad, San Diego, CA, USA).
Results
Median age was lower for SS patients
(28 years, range: 13 to 52 years) than for
SC patients (38.5 years, range: 17 to 72
years), with the difference being almost sta-
tistically significant (P = 0.059). Median
hemoglobin level was lower for SS patients
(7.95 g/dL) than for SC patients (11.53 g/
dL), whereas fetal hemoglobin level was
higher for SS patients (6.2%) than for SC
patients (2.1%). These differences were both
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significant (P < 0.001).
The vascular complications investigated
in the present study were more frequent in
SC patients (83.3%) than in SS patients
(34.5%), as shown in Table 1. Retinopathy
was significantly more frequent in SC pa-
tients, as expected, whereas acute thoracic
syndrome was only recorded among SS pa-
tients (Table 1).
Only one patient was heterozygous for
the factor V Leiden mutation (1.8%) and
there was no prothrombin G20210A muta-
tion. Because of the low frequency observed,
the relationship between these mutations and
other epistatic factor was not considered
further.
MTHFR 677TT polymorphism was de-
tected in 1 patient (1.8%) and the heterozy-
gous form 677TC was observed in 18 pa-
tients (34%), 9 with SS and 9 with SC dis-
ease. No association was detected when we
compared the presence of the MTHFR 677T
allele and other genetic modulation factors
such as α-thalassemia, ß-globin gene haplo-
type and fetal hemoglobin.
The presence of the MTHFR 677T allele
was associated with the occurrence of vas-
cular complications in SCD, although this
association was not significant if each com-
plication is considered separately (Table 2).
Taking all 4 complications together, the OR
was 4.8 (95% CI: 1.3-17.3, P = 0.020). The
association was still significant when we
considered stroke, retinopathy and AVN,
with an OR of 3.5 (95% CI: 1.1-11.5, P =
0.047).
Discussion
Although HbS cells are indispensable for
the generation of the disease, several other
phenomena, affected by a multitude of genes
other than the one directly mutated (epistatic
effect), play an important role (15). The
importance of thrombosis in the pathophysi-
ology of SCD has been recently recognized.
Considerable evidence suggests that endo-
Table 1. Prevalence of stroke, avascular necrosis (AVN), retinopathy, and acute
thoracic syndrome (ATS) in patients with sickle cell disease (SCD).
SCD patients SS patients SC patients
(N = 53) (N = 29) (N = 24)
Cases with vascular complication 30 (56.6%) 10 (34.5%) 20 (83.3%)*
Stroke 1 (1.8%) 1 (3.4%)   0 (0.0%)
AVN 2 (3.8%) 1 (3.4%)   1 (4.2%)
Retinopathy 16 (30.1%) 1 (3.4%) 15 (62.5)
ATS 4 (7.5%) 4 (13.8%)   0 (0.0%)
Combined complications# 7 (13.2%)  3 (10.3%)   4 (16.7%)
Episodes of vascular complication
Stroke 3 (5.6%) 3 (10.3%)   0 (0%)
AVN 8 (15.1%) 3 (10.3%)   5 (20.8%)
Retinopathy 21 (39.6%) 2 (6.9%) 19 (79.2%)*
ATS 6 (11.3%) 6 (20.7%)   0 (0%)*
SS = sickle cell anemia; SC = sickle-hemoglobin C disease.
#4 patients had AVN + retinopathy; 1 patient had stroke + AVN; 1 patient had stroke +
ATS; 1 patient had AVN + retinopathy + ATS.
*P < 0.05 compared to SS (Fisher’s exact test).
Table 2. Odds ratio for the association between the 677T allele and vascular complica-
tions in sickle cell disease.
MTHFR Vascular complication Odds ratio   95% CI
AVN + AVN -
CC 3 31 1#
CT/TT 5 14 3.7 0.8-17.7
R + R -
CC 11 23 1#
CT/TT 10 9 2.3 0.7-7.4
ATS + ATS -
CC 3 31 1#
CT/TT 3 16 1.9 0.4-10.7
Stroke + Stroke -
CC 2 32 1#
CT/TT 1 18 0.9 0.08-10.5
AVN + R + stroke No AVN, R or stroke
CC 13 21 1#
CT/TT 13 6* 3.5 1.1-11.5
AVN + R + stroke + ATS No vascular complication
CC 15 19 1#
CT/TT 15 4* 4.8 1.3-17.3
AVN = avascular necrosis; R = retinopathy; ATS = acute thoracic syndrome.
#Reference risk factor. *P < 0.05 for comparison between patients with and without
vascular complication with regard to the distribution of the allele 677T (Fisher’s exact
test).
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thelial damage and thrombosis play impor-
tant contributory roles in the vaso-occlusive
complications of SCD (10,16).
We found only 1 patient in 53 SS + SC
subjects heterozygous for factor V Leiden
and no patient with prothrombin mutation,
as expected, since these polymorphisms are
more frequent in Caucasians.
The MTHFR 677TT genotype was de-
tected in 1.8% of SCD patients, which is
similar to the prevalence reported by others,
ranging from 1 to 2.8% (17-20). Balasa et al.
(18) found a prevalence of 1% for this geno-
type among 110 normal American Blacks,
whereas its prevalence among Caucasians
ranges from 10 to 20%, depending on the
geographic distribution (21-26). In Brazil,
despite the great miscegenation, there seems
to be a high proportion of Caucasians within
normal individuals, since Morelli et al. (27)
reported a 9% prevalence of 677TT and
Franco et al. (28) found a 16.6% prevalence.
We found that the 677T allele was asso-
ciated with vaso-occlusive complications in
patients with SCD. Some investigators did
not find an association between MTHFR
C677T and clinical manifestations in SCD:
Cumming et al. (17) evaluated stroke in SS
patients and Zimmerman et al. (19) evalu-
ated the occurrence of stroke and AVN in
SS, SC and Sß0 thalassemia patients. In a
Brazilian study conducted on 73 patients
with sickle cell anemia, SC hemoglobinopa-
thy and Sß0 thalassemia, none presented ho-
mozygosity for the MTHFR 677T allele,
including those with vascular complications
such as stroke or deep vein thrombosis (29).
On the other hand, Kutlar et al. (30) found a
significant association between the 677T al-
lele and AVN in SS patients, which has also
been reported in individuals without SCD
(31).
Hyperhomocystinemia is a significant risk
factor for venous thrombosis in patients with-
out known acquired thrombophilia or other
genetic risk factors for venous thrombosis,
underscoring the importance of homocys-
teine evaluation in thrombotic disease (27).
The role of moderate hyperhomocystinemia
as a cause of stroke in adults has been well
documented, and it has been suggested that
high homocysteine levels may be a risk fac-
tor for the development of stroke in patients
with SCD as well (32). Morelli et al. (27)
found that homocystinemia levels are sig-
nificantly higher in homozygotes for the
MTHFR C677T mutation both in patients
with venous thromboembolism and controls.
Chronic ongoing hemolysis in sickle cell
patients causes a high demand for folate,
necessary for normal erythropoiesis. The
presence of the 677T allele, which is associ-
ated with high homocysteine levels, may ag-
gravate the effect of this amino acid on the
vascular system. Actually, Houston et al. (33)
showed a clear influence of hyperhomocystine-
mia on the risk of stroke in SS patients, al-
though their folate status was normal.
In conclusion, our data suggest that
MTHFR C677T polymorphism might be a
risk factor for vascular complications in SCD,
probably contributing to the deleterious ef-
fect of hyperhomocystinemia caused by
folate imbalance.
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